

Impactability Modelling Population Health Management Working Party



Impactability Modelling

Population Health Management Working Party

5th June 2019

25 June 2024



Introduction

Background to the Working Party

Alpesh Shah

25 June 2024

Introduction & Background

- The changing NHS landscape
- Role of Population Health Management
- Genesis of the PHM working party
- Focus on Impactability
- How we have organised ourselves:
 - Definition
 - Methods & Models
 - Practical Challenges
 - Ethics and Patient View





Definitions of Impactability

Overview, principles, problem statements

Joanne Buckle

Overview in "layman's terms"

IMPACTABILITY

Identifying groups of people who would benefit most from specific treatments, interventions and support as part of a Population Health Management strategy

What is Impactability modelling?

Impactability modelling allows a health system to identify the interventions or changes in care to which people are most likely to respond positively.

What are the benefits?

Impactability modelling enables care provision to be aligned to people's needs in a way that achieves better health outcomes within limited health resources.

How does this relate to Risk Stratification?

Risk stratification identifies people most likely to experience adverse health outcomes; whereas impactability suggests which changes to care are most likely to lead to better health outcomes.

Our technical definition: *"Impactability modelling measures the degree to which different subpopulations will benefit from a range of interventions and supports using this information to tailor appropriate interventions, within agreed boundaries, to optimise the 'value' gained from resources spent"*



Principles that define impactability modelling

Cohorts	Focused on population-defined cohorts likely to be predictive of future risk of sub-optimal health outcomes, rather than just disease-defined. These could include socio-economic groups.	Policy driven	Facilitates achievement of overall policy goals for health service, such as "equal opportunity for equal need"
Time dimension	Time frames ranging from short term (1 year) to decades	Distributions not just mean	Incorporates consideration of the distribution of outcomes, rather than just shifting the mean outcome
Outcomes	Incorporates a range of outcomes, rather than just resource-use/financial, for example, healthy life years, mortality, quality of care (at an individual and population level), staff/ patient satisfaction improvements	Evaluation methodology	Up-front incorporation of evaluation of intervention, along with consideration of appropriate methodology, tools and data required to overcome issues such as regression to the mean, selection bias, sample size etc.

Ethics dimension

Incorporate of patient-preference or patient willingness, as well as clinically-defined need



Example problem statements that would benefit from impactability modelling

We would like to understand which sub-populations are most likely to benefit from different health and care pathways, while considering the impact on inequality of outcomes. We would like to identify gaps in care for different sub-populations and identify the best ways to fill those gaps. We have an intervention and we want to understand the relative impact for different population groups. For example, we might want to understand the financial or other cost-benefit for prescribing a certain drug to one group of patients versus a group with different characteristics or risk factors.

- We want to understand the clinical value gain overall and the distribution of the clinical value gain from targeting a set of tailored interventions to groups sub-divided according to socio-economic characteristics.
- What is the likely capacity of a specific set of patients at risk of AF, hypertension, hyperlipidaemia to benefit clinically from anticoagulants? What is the financial RoI over a specified time period?
 - · We want help in deciding which patients will benefit from statins versus another intervention?

Specific Statements

- If we want to offer gripped slippers to a group at risk of frailty, how do we decide which sub-groups are at greatest risk or who will benefit most?
 - If we have three potential care pathways for chronic depression as a co-morbidity, how can we effectively match each care pathway to the set of people most likely to benefit and understand the impact on overall clinical outcomes, as well as distribution of outcomes in each cohort and across cohorts?





Methods & Models

Data-driven, applying actuarial skillset

David Beddows

Methods for impactability modelling

Many potential approaches

"Traditional" Approaches

Prioritise patients with:

- high gap score
- high weighted gap score.
- one or more ambulatory care sensitive conditions

De-prioritise patients with:

- stable characteristics
- extremely high risk

Impactable moments

 e.g. post discharge from hospital

"Data-driven" / Statistical Approaches

- Risk stratification / risk
 scores
- Rising risk score (rate of change of risk score)
- Comparing service utilisation, risk characteristics and condition severity against benchmarks
- Data science methods: clustering; decision trees; neural networks.

Other

Questionnaires/frameworks for assessing individual patients, e.g.:

- Patient Activation
 Measure
- ANGEL score



Methods for impactability modelling

Pros and cons of the various approaches

"Traditional" Approaches

Pros

- · Widely accepted
- Clinicians know how to do it
- Patients trust

Cons

- Time consuming
- Data quality
- Cognitive biases

"Data-driven" / Statistical Approaches

Pros

- Objective
- Quicker than working through all the individual medical records
- Proactive
- Better population health outcomes

Cons

- Requires high quality data
- Requires new/more technology
- Bias in data and model
- Questionable predictive accuracy

Considering the actuarial skillset, the WP is naturally focussing on the datadriven/statistical methods



Data for impactability modelling

Current health policies and advances in technology offer opportunities to develop more "data-driven" methods





of Actuaries

Criteria for model assessment (1 / 2)

Appropriateness of methods for use and for further investigation by this WP

Patient/population health & Pat	ient experience	Healthcare resource utilisation		
Patient Outcomes	Patient Experience	Resource Utilisation / Cost	Technology	
Which outcomes are most interesting?	Does the impactability assessment result in patients needing more appointments /	Resources needed for performing the impactability assessment and the resulting	Is the necessary technology available?	
Can they be measured?	procedures / diagnostic tests?	net effect on clinician/system resources of implementing the	Processing power of hardware	
Time frame		Burden of data collection &	Do people know how to use the technology?	
Measures of success?		analysis		
		 staff involvement clinicians training Raising awareness 		



Criteria for model assessment (2 / 2)

Appropriateness of methods for use and for further investigation by this WP

Healthcare professional experience	Actuarial Concerns			
Staff Experience	Data Availability	Professionally / Clinically / Academically Rigorous	Suitability for this WP to research further	
Increase workload? Are staff sufficiently trained in the procedures / techniques / understanding results of the analysis? Recruitment necessary	Sufficient data? How quickly can it be accessed? Data history Individual level data Data quality Data privacy, information	Solid theoretical bases? Clinically sound? Are the methods transparent? Peer reviewed? Are assumptions justified? Bias	Can actuaries add value to the field regarding each model? E.g. the data-driven approaches would tend to lend themselves more to actuarial skillset	
	governance, ODFN, elc	Regression to mean	2 A C	





Practical considerations

What are the barriers and enablers to effective impactability modelling

Dr. Chris Martin

Practical considerations

- Eight interviews conducted so far with stakeholders and experts.
- Grounded thematic analysis of interview notes.



Practical issues 1

Impactability modelling

Risk stratification

- Intangible disease subgroups.
- Anxiety in patients.
- Risk model failure.
- New methods such as AI.

Impactability

- Organisational features as well as patient.
- Risk scores can only be fitted to the data available.

Identification of risk and impactability thresholds.

Organisational factors

- Surviving organization reforms.
- Relationships and morale.
 - Local trumps national.
 - Engagement, trust and motivation.
 - Affects multidisciplinary team implementation.
- Inter-operability of records systems.
- Training issues and understanding.



Practical issues 2

Data	Analysis
 Consistent, complete, precise, sufficient. 	 Huge demand and a lack of capacity.
Incompleteness	 Diversion of analyst resources to statutory returns.
Lack of standardisation.	
 Data availability and usefulness not the same. 	• Communication of results is a problem.
	 Needs to be system wide and not at
 Data for stratification a secondary purpose. 	component level.

| Institute and Faculty of Actuaries

• Poor sharing of data.

Practical issues 3

Evaluation

- Understand the logic model first.
- Perspective affects performance metric.
- Outcome more important than adherence.
- Requires the passage of time.
- Causation can't be inferred with pre/post studies.
- Impactability important for evaluating the cost-effectiveness of interventions as well as for identifying targets for intervention.

Potential solutions

- To improve access.
- •
- To increase the supply of analytic skills to population health management:
- Support for organisations in understanding segmentation, risk stratification and impactability.
- A phased approach to systems integration across organisations may have a greater chance of success.





Ethics & Patient View

Sarah Culkin



Ethics and Patient Involvement

 Range of ethical considerations when developing an Impactability model:





Ethics: Data In

🗇 GOV.UK		Search	٩
Home > Data Ethics Framework			
Department for Digital, Culture, Media & Sport			
Guidance Data Ethi Updated 30 August 2018	s Framework		
Contents Ministerial Foreword	Ministerial Foreword		



Ethics: Decision Support Out

Traditional Medical/Public Health bioethics

Example:

• Utility	1. Value/s	2. DRG-specific factors Cost & efficiency	Macro-level (D) Do DRGs help to contain costs for the health care system?	Meso-level (D) Is efficiency under DRGs correlated with the kind of hospital providing the service?	Micro-level (M) What if anything can we learn about the impact of DRGs from HCPs' perceptions of efficiency?
Benefits	Producing benefits	Quality of care	How should we define and mea good quality of health care?	(D) How is patient safety affected by the implementation of DRGs at specific hospitals?	(D) How if at all do DRGs influence the quality of care for individual patients?
JusticeTransparency	Distributive justice	Access to health care	(N) Is sufficient access to health care a fundamental requirement of justice?	(D) Do DRGs affect access to care at specific hospitals?	(D) What are HCPs' perceptions of how vulnerable groups are affected by DRGs?
 Autonomy 	Iransparency	Hospital transparency Patient autonomy	(D) Do DRGs result in greater pricing transparency? M) What is patient	(D) Are hospital procedures conducive to promoting transparency? (D) Do DRGs lead to	(M) How if at all can hospital transparency be judged at a micro-level? (D) How if at all do
		· · · · · · · · · · · ·	autonomy and how should it be measured?	greater competition between specific hospitals and does this impact on patient choice?	DRGs affect the autonomy of individual patients e.g. through an impact on informed consent?



Q & A

All





The views expressed in this presentation are those of invited contributors and not necessarily those of the IFoA. The IFoA do not endorse any of the views stated, nor any claims or representations made in this presentation and accept no responsibility or liability to any person for loss or damage suffered as a consequence of their placing reliance upon any view, claim or representation made in this presentation.

The information and expressions of opinion contained in this publication are not intended to be a comprehensive study, nor to provide actuarial advice or advice of any nature and should not be treated as a substitute for specific advice concerning individual situations. On no account may any part of this presentation be reproduced without the written permission of the IFoA.



Contact details

- Alpesh Shah alpesh.shah@pwc.com
- Joanne Buckle joanne.buckle@milliman.com
- David Beddows david.beddows@optum.com
- Dr. Chris Martin chris.martin@crystallise.com
- Sarah Culkin sarah.culkin@nhsx.nhs.uk

